STAT

DECEMBER 12, 2023

These drugs have price tags of $2.2 This approach has been around for decades but required patients to have a well-matched donor and endure a hefty dose of chemotherapy, ruling out transplant as an option for the vast majority of patients. million and $3.1 million, respectively.

Chemotherapy 124

Chemotherapy Immunization 124

pharmaphorum

DECEMBER 23, 2021

After EGFR therapy fails, platinum-based chemo has limited efficacy, generally preventing disease progression or death for between four and six months. Daiichi Sankyo has now started a phase 2 trial – called HERTHENA-Lung01 – in 420 patients with EGFR-mutated NSCLC previously treated with at least one EGFR inhibitor and platinum-based chemo.

FDA 71

FDA Chemotherapy 71

pharmaphorum

APRIL 27, 2022

The top-line results showed that Enhertu (trastuzumab deruxtecan) achieved a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) when compared to physicians’ choice of chemo.

Chemotherapy 58

Chemotherapy FDA 58

pharmaphorum

OCTOBER 29, 2021

Gilead is sponsoring the new study to see if adding Trodelvy can be an alternative chemo when added to Keytruda in the first-line treatment of advanced TNBC, in the hope of moving the ADC up the treatment pathway. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on.

Chemotherapy 52

Chemotherapy FDA 52

European Pharmaceutical Review

DECEMBER 27, 2023

Other examples include the absence of age requirement/limitation for CAR T-cell therapy and that chemo sensitivity is not mandatory for CAR treatment. This is in addition to its considerable price tag. 6-8 Clinical recommendations also change.

Adverse Reactions 93

Adverse Reactions Immunization Medical Schools Chemotherapy 93